Chiesi Farmaceutici
 | |
| Company type | Società per Azioni, (S.p.A.) (something like a Joint-Stock company) |
|---|---|
| Industry | Pharmaceuticals |
| Founded | 1935 |
| Headquarters | , |
Key people | Alberto Chiesi (President) Paolo Chiesi (Vice-president & Director of R&D) Ugo Di Francesco (CEO) |
| Revenue | €1.690 billion (2017) |
Number of employees | 5300 |
| Website | http://www.chiesigroup.com |
Chiesi Farmaceutici S.p.A. is a family controlled[1][2] Italian pharmaceutical company based in Parma, Emilia-Romagna.
Following the acquisition, in 1999, of Huddersfield based Trinity Pharmaceuticals, Chiesi has also had a significant presence in the United Kingdom.[3]
Established in 1935, Chiesi concentrates primarily on developing respiratory, cardiovascular and neonatological drugs, along with those for treating muscular and skeletal conditions. As well as developing drugs in-house, Chiesi has a policy of developing drugs in collaboration with pharmaceutical businesses outside Italy.
The Company employs approximately 5300 people within and beyond Italy. It holds 550 international patents, and employs approximately 720 people dedicated to Research and Development activities, including regulatory in the R&D centres in Parma, Paris, Cary (North Carolina, USA), Chippenham (UK), Oxford (UK), and Sweden.
2010 was the year in which turnover broke through the Billion Euro barrier, with Chiesi recording sales growth of 16.4% over the figure for 2009. By 2013 turnover had reach €1,236, [verification needed] with increases coming primarily from outside the Italian home market. [4] Chiesi Farmaceutici closes 2016 on a high with an annual turnover of €1.571 million, an increase of more than +7.0% on the previous year (+9.6% at constant exchange rates), and EBITDA equal to €448 million (a year-on-year increase of over 8.2%). The robust health of the company is reflected by its investment in innovation and development, with R&D expenditure rising by over +12.5% in the 2015-2016 period to reach €340 m in 2016, 21% of total sales. The Group currently has 51 active research and development projects. [5]
Notes and sources
- ^ In July 2014 the company website shows a Consiglio di Amministrazione (Board of Directors) comprising eight individuals. Six of these are named "Chiesi"
- ^ "Chiesi Farmaceutici S.p.A." www.chiesigroup.com.
- ^ http://www.chiesi.uk.com/about_chiesi/
- ^ "Chiesi Farmaceutici S.p.A.: Private Company Information - Bloomberg". investing.businessweek.com.
- ^ "Chiesi Group reports an increased turnover in 2016 and consolidates its global presence".